Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
SALT LAKE CITY, Dec. 21, 2017 -- PolarityTE, Inc. (NASDAQ:COOL) today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-9, 2018.
To schedule a meeting with PolarityTE, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].
About PolarityTE
PolarityTE, Inc. is a regenerative medicine company, and the first to successfully regenerate full-thickness tissue. The Company's novel regenerative medicine platform and proprietary technology employs a patient's own cells for the healing of full-thickness, functionally-polarized tissues. If clinically successful, the PolarityTE™ platform will provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the potential regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The PolarityTE™ platform leverages natural and biologically-sound principles which are readily adaptable to a wide spectrum of organ and tissue systems. This revolutionary technology, paired with the Company's world-renowned clinical advisory board, position PolarityTE™ to drastically change the field and future of translational regenerative medicine. More information can be found online at www.PolarityTE.com.
CONTACT
John Stetson
[email protected]
(385) 237-2365
Investors:
Hans Vitzthum
LifeSci Advisors, LLC
617-535-7743
[email protected]
